ADVANCED SOLID TUMORS

This study tests an experimental drug called marlotamig (REGN7075) alone or with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors or slow cancer growth. About 933 participants…

This early-stage study tests a new cell therapy called GK01 in 10 people with advanced lung or esophageal cancer that no longer responds to standard treatments. The main goal is to check if the treatment is safe and tolerable. Researchers will also measure how long the cells stay…

This early-phase study tests a new drug, YL211, in about 155 adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose; second, confirming that dose; and third, checking how well it works. The main goal…

This study tests whether giving a targeted therapy drug that matches a specific gene change in a person's cancer can shrink tumors or stop them from growing. It includes adults with advanced solid tumors, multiple myeloma, or certain lymphomas who have no standard treatment optio…

This early-stage trial tests a new drug called SIBP-A19 in 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants will receive the dru…

This early-stage study tests a new oral drug, ZX-8177, in about 80 Chinese adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants take the d…

This study tests a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 adults who have tried all available treatments will take part. The study is curr…

This early-phase study tests a new drug called 177Lu-RAD202 in 30 adults with advanced solid tumors that have a protein called HER2. The drug uses a radioactive particle to seek out and attack cancer cells. The main goals are to check safety, find the right dose, and see how the …

This early-stage study tests a new drug called BGM-2121 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. It is a first step to see if the drug might help control the d…

This study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…

This early-stage study tests a new drug called BAT8008 in 182 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants receive the drug and are m…

This early-phase study tests a new drug, GenSci140, in about 170 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors, especially in ovarian cancer. Partici…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs can shrink tumors. About 240 a…

This study tests an experimental mRNA treatment, mRNA-4359, for people with advanced solid tumors that have not responded to standard therapies. The treatment is given alone or with other immune-boosting drugs to see if it is safe and can shrink tumors. About 361 adults will take…

This early-phase study tests an experimental drug called SKB445 in 126 adults with advanced solid tumors that have not responded to or are not eligible for standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Pa…

This early-phase study tests a new treatment called Meta10-TIL, which uses a patient's own immune cells that are modified to better fight cancer. The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors who have already tried at least one standa…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check safety and find the right dose. This is an early-phase trial, so it foc…

This early-stage study tests a new drug called HS-20122 in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 1,050 participants will receive the drug intravenously and be closel…

This study tests a new drug called SHR-A1904 in people with advanced solid tumors, specifically stomach or pancreatic cancer that has not responded to other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 83 adults will take part in th…

This early-stage study tests the safety of a new drug called FID-022 in about 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find the highest safe dose and identify side effects. Participants will receive FID-022 alone, an…

This study tests a new daily pill, ABP1011T, in people with advanced solid tumors like small cell lung cancer, esophageal cancer, and others that have stopped responding to standard treatments. About 110 participants will take one tablet each day on an empty stomach in 21-day cyc…

This early-phase study tests a new drug called HRS-3802 in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the…

This study tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, while also see…

This early-phase trial tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better attack cancer. The main goal is to check sa…

This early-phase study tests a new injection called SHR-3821 in 162 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Participants must be 18-75, in …

This early-stage trial tests a new drug called E303 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the drug …

This early-phase study tests a new drug called Hemay181 in 24 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goal is to see if the drug can shrink tumors and to check for side effects. Particip…

This study is for people with advanced solid tumors that cannot be removed by surgery or have spread. It tests a combination of sirolimus (a drug that may slow cancer growth) with different antibody-drug conjugates (ADCs, which deliver cancer-killing drugs directly to tumor cells…

This early-phase study tests a new drug called INCA33890 in about 408 adults whose solid tumors have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants must have tried other treatments first or be …

This study tests a new drug called CM518D1 in about 434 adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely mon…

This study tests a new drug called HRS-6768 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can help control the disease. About 84 participants will be enrolled in this early-phase trial.

This study tests an experimental pill, VVD-133214, in people with advanced solid tumors that have a specific genetic feature called MSI or dMMR. The drug targets a protein (Werner) that helps these cancers grow. The main goal is to check safety and find the right dose, with up to…

This study tests a new drug called LCB84, which targets a protein (TROP2) on cancer cells, for people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or with an immunotherapy (anti-PD-1 antibody). The goal is to find the saf…

This early-phase study tests an experimental drug called SBO-154 in about 177 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The main goals are to check the drug's safety and find the right dose, while also looking for any sig…

This early-stage trial tests a new drug called DT-7012, alone or with another cancer drug, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to check safety and see if the drug can shrink tumors. About 125 people will take part.

This early-stage study tests a new drug called ASP1002 in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find a safe dose, and see how well people tolerate it. Participants receive the drug thr…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This study tests a new drug (YL201) combined with ivonescimab in 260 adults with advanced solid tumors, including lung cancers. The goal is to see if the combination is safe and can shrink tumors. Participants must have good organ function and not be eligible for local curative t…

This study tests a new drug, SKB103, in about 277 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments or for which no standard therapy exists. The goal is to find a safe dose and see if the drug can shrink tumors. The study is currently rec…

This study tests a new drug called YL205 in 252 adults with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants receive YL205 and are closely monitored for s…

This early-stage trial tests a new drug called ALTA3263 in adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety and find the right dose. About 188 people whose cancer has worsened after stand…

This study tests a new drug, SKB105, in 256 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has three parts: starting with low doses to check safety, then expan…

This early-phase study tests a new drug, OKI-219, designed to block a specific cancer-driving mutation (PI3KαH1047R). It is for people with advanced solid tumors or breast cancer that has not responded to other treatments. The study will first find the safest dose of OKI-219 alon…

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 862 adults will take part in this early-phase trial a…

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors. The goal is to find safe doses and see if the combination can shrink tumors. About 876 adults aged 18-75 with advanced cancer that has not responded to standar…

This early-stage study tests a new drug called GS-2121, alone or with another drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 154 participants will take part.

This study tests an experimental drug called AMT-253 in people with advanced melanoma or other solid tumors that have spread or cannot be removed. The goal is to see if the drug can shrink tumors or slow disease progression. About 96 participants will receive the drug in two phas…

This early-phase study tests a new drug called BG-C477, alone or with other cancer treatments, in people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About …

This early-phase study tests an experimental oral drug called ST-01156 in people with advanced solid tumors (including Ewing sarcoma, liver cancer, and bile duct cancer) that have not responded to standard treatments. The drug works by breaking down a protein (RBM39) that cancer …

This study tests an experimental drug called MRG006A in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. About 343 adults aged 18 to 75 will take part in this early-pha…

This study tests an experimental drug called OTP-01 in about 170 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to attack cancer in two ways—by blocking PD-1 and VEGFR2—to shrink tumors and slow disease. The main goals are t…

This early-phase study tests an experimental drug called PAS-004 in about 48 adults with advanced solid tumors that have certain gene mutations (RAS, NF1, or RAF). The main goal is to find a safe dose and understand side effects. Participants take the drug by mouth daily for up t…

This early-stage study is testing a new drug, SIM0505, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 414 people will take part, and researchers will also look for a…

This early-phase study tests a new drug called SKB315 in about 246 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have tumors …

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or stop them from g…

This study tests a new drug called ALK201 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 202 adults aged 18 to 75 will take part in this ea…

This study tests a combination of experimental drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink or control tumors. About 370 participants whose cancer has worsen…

This early-phase study tests an experimental drug called HDM2006 in 48 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug…

This study tests a new drug, CKD-703, for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to cancer cells that have a specific ma…

This early-stage study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety and find the right dose, and to see if the …

This study tests a new drug called SPR1020 in 210 adults with advanced solid tumors that have not responded to standard treatments. The drug aims to shrink tumors by targeting a specific DNA repair pathway, and may also work in the brain. The main goals are to find the safest dos…

This early-phase study tests an experimental oral drug called ATX-295 in about 90 adults with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also …

This early-stage study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. About 200 adults with certain types of kidney, ovarian, uterine, colorectal, or…

This early-phase trial tests the safety and best dose of a new drug called BTM-3566 in 30 adults with advanced solid tumors that have not responded to standard treatments. Participants take the drug for 7 days, then pause for 7 days, repeating until the cancer worsens or side eff…

This study tests a new drug called GFH375 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 407 adults aged 18 to 75 with advanced c…

This early-stage study tests a new oral drug, TYRA-430, in about 100 adults with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find a safe dose and check for side effects. Researchers will also look for si…

This study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS alteration). The goal is to find the safest dose and see if the drug can shrink tumors. About 294 participants will take the drug by mouth, and researchers …

This early-stage trial tests a new drug called HW071021 in 76 adults with advanced solid tumors (cancers that have spread or come back). The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body and wheth…

This study tests an oral drug called BAY 2927088 in people with advanced solid tumors that have HER2 mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. About 111 adults with various cancers (excluding lung cancer) will take the drug daily until th…

This early-phase study tests a new drug called AK146D1 in 200 people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two targets on cancer cells to deliver a powerful anti-cancer agent. The main goals are to check …

This early-stage trial tests a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then, refining the dose; and finally, checking how well it works in more patients. About 121 participants will receive t…

This study tests an experimental drug called BMS-986490, given alone or with bevacizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The tumors must have a specific marker called CEACAM5. The main goals are to check safety and find …

This early-phase study tests a new drug called MK-1084, alone or with other treatments, in people with advanced solid tumors that have a specific KRAS G12C mutation. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 830 participant…

This early-phase trial is testing whether adding an experimental drug (AT1019) to standard radiation and immunotherapy is safe for people with advanced solid tumors. About 12 adults whose cancer has not gotten worse on immunotherapy will receive the combination. The main goal is …

This study tests a new drug called SPH4336, given alone or with another drug called cadonilimab, in people with advanced solid tumors (including a type of liposarcoma). The goal is to see if the treatment can shrink tumors or slow their growth. About 63 participants will take par…

This early-stage study tests a new drug called SIGX1094R in about 102 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how food affects it. Researchers will also look for s…

This early-stage trial tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have stopped responding to standard treatments. The study has three parts: first finding a safe dose, then checking how wel…

This study is for people with advanced solid tumors that have a specific genetic mutation called KRAS G12D. The trial tests a new drug, HRS-4642, combined with other anti-cancer medicines to see if it is safe and helps shrink tumors. About 118 adults aged 18 to 75 with good perfo…

This study tests an experimental drug called EIK1005, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the combination can shrink tumors. About 160 adults with …

This early-phase trial tests an experimental drug called TEV-56278, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can…

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink or control tumors. About 156 p…

This study offers continued access to sotorasib (with or without panitumumab) for adults with advanced solid tumors who have a KRAS G12C mutation and were already benefiting from the drug in a previous Amgen trial. The main goal is to monitor safety and side effects over time. Ab…

This study tests a new drug called BMS-986482, given alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to check safety and how well the drug works. About 413 adults with various advanced cancers will t…

This early-phase study tests a new drug called CKD-512, given alone or with pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see early signs of tumor shrinkage. About 60…

This study tests a new drug called ASKG915 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see how the drug works alone or with usual care. About 594 participants will take part in this early-phase tria…

This early-stage study is testing a new drug called GenSci139 in 280 people with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. This is the first time GenSci139 is being tested in humans.

This early-stage study tests a new drug, BMS-986504, in up to 32 Japanese and Chinese adults with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and how the body processes it. Participants must have tried o…

This early-stage study tests a new drug, ACR246, in about 77 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will receive ACR246 and be close…

This early-stage study tests a new drug called PHN-012, which is designed to deliver a powerful cancer-killing agent directly to tumor cells. It is for people with advanced colon, pancreatic, or lung cancer who have tried other treatments without success. The main goals are to ch…

This early-phase study is testing a new treatment called JNJ-87704916, a virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors, either alone or combined with another drug (cetrelimab). The study aims to find the safest dose and check …

This early-stage study tests a new treatment called NK042 for people with advanced solid tumors that have not responded to standard therapies. The treatment uses specially designed immune cells to attack the cancer. The main goals are to check safety and see if the treatment can …

This early-stage study tests a new tablet called GEN-725 in about 48 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose, while also looking for signs that it can shrink tumor…

This early-phase study tests a new drug, FS-8002, in 66 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps control the cancer. Participants will receive FS-8002 a…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and whether it can shrink tumors. About 110 participants will receive the drug, an…

This early-stage study tests a new drug, FP008, in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether it c…

This early-phase study tests a new drug called ABX-001, given alone or with an immunotherapy (pembrolizumab), in adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety and find the best dose. About 27 participants will …

This early-phase study tests a new drug called FORX-428 in people with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goal is to find a safe dose and see how the drug affects the cancer. About 40 adults who have already tried standard trea…

This study is testing a new medicine called SNV4818 for people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 320 participants will receive…

This early-stage study tests a new injection form of the cancer drug rilvegostomig in about 40 adults with advanced solid tumors that have already been treated. The goal is to find a dose that works as well as the current IV version and to check for side effects. Participants mus…

This early-phase trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. The study includes adults with pancreatic, breast, or other solid t…

This study tests an experimental drug called WJB001 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 210 adults will take part in three phases: starting with lo…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. About 272 people with cancers like ovarian, end…

This study tests a new drug called YL202 combined with other cancer treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to find a safe dose and see if the combination shrinks tumors. About 414 adults aged 18-75 who have tried standard tr…

This early-stage study tests a new drug called TGW101 in about 50 adults with advanced solid tumors that have worsened after standard treatments. The main goal is to check safety and find the best dose. Researchers will also look at how the drug moves through the body and whether…

This study tests a new drug called CS2009, which targets three different proteins on cancer cells to help the immune system fight tumors. It is for people with advanced solid tumors that have not responded to other treatments. The trial has two parts: first, finding the safest do…

This early-phase study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. Doctors take immune cells from a patient's own tumor, grow them in a lab, and infuse them back into the patient. The goal is to see if this approach i…

This early-phase study is testing a new drug called GenSci143 in 180 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receiv…

This early-phase study tests a new drug called SKB500 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at whether the drug can shrink tumors. Pa…

This early-phase study tests a new drug, VVD-159642, designed to block key signals that help cancer cells grow. It is for people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have not responded to other treatments. The study will first find a safe …

This early-stage study tests a new tablet, JMKX005425, in about 100 people with advanced solid tumors that have specific genetic changes (MSI-H or dMMR). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have tumors …

This early-phase trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also compare different doses in people with head and …

This study tests a new drug, ETX-636, for people with advanced solid tumors (like breast cancer) that have a specific genetic change called PIK3CA. The drug is designed to block a faulty protein that helps cancer grow. The trial will first test the drug alone, then in combination…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 130 adults w…

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment combines a modified virus (hV01) that targets and kills cancer cells while boosting the immune system, with an immunotherapy drug (tislelizumab) tha…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This study tests an experimental drug, VIB305, in people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. The trial has two parts: first, finding the safest dose, and then testing that dose in more patients to see if it shrinks t…

This study tests a new drug called SKB518 for the first time in humans. It is for adults with advanced solid tumors that have stopped responding to standard treatments or have no effective therapy available. The main goals are to check the drug's safety, find the best dose, and s…

This study is the first time VVD-130037 is being tested in humans. It aims to find out if the drug is safe and can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 290 participants will receive the drug alone or combin…

This early study is testing a new imaging agent called FL-261 to see if it can safely and accurately detect and stage several types of cancer, including lung, colorectal, and head & neck cancers. The agent targets a protein (c-MET) found on many cancer cells but not on most healt…

This study tests whether wearing a compression stocking on one foot during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by certain cancer drugs. About 58 adults with advanced bladder or related cancers will participate, with the left foot covered and the r…

This study looks at how the antifungal drug itraconazole changes the levels of the cancer drug HS-20093 in the body. It involves 18 adults with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The goal is to understand the interaction to hel…

This study is for people with advanced cancer (solid tumors, lymphoma, or multiple myeloma) that has stopped responding to standard treatments. Researchers will test the tumor's genes to find a targeted drug that might work. The goal is to learn from real-world use which drugs he…

This study looks at how the drug pralatrexate is processed by the body in people with advanced solid tumors or blood cancers who also have mild, moderate, or severe liver problems. Researchers will measure drug levels in the blood and track side effects. The goal is to find the r…

This early-phase study looks at how a new drug called rezatapopt changes the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C mutation. About 14 participants w…